Guggenheim Capital’s Protalix BioTherapeutics PLX Stock Holding History

Guggenheim Capital’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-4,038	Closed	-$22K	–	2543
2018 Q1	$22K	Buy	4,038 +24	+0.6%	+$158	﹤0.01%	2740
2017 Q4	$27K	Sell	4,014 -501	-11%	-$3.38K	﹤0.01%	2659
2017 Q3	$26K	Buy	4,515 +451	+11%	+$2.89K	﹤0.01%	2730
2017 Q2	$34K	Hold	4,064	–	–	﹤0.01%	2751
2017 Q1	$55K	Buy	4,064 +24	+0.6%	+$216	﹤0.01%	2727
2016 Q4	$18K	Hold	4,040	–	–	﹤0.01%	2856
2016 Q3	$23K	Buy	+4,040	New	+$25.2K	﹤0.01%	2816

Other funds holding PLX

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Guggenheim Capital's PLX Position: Q2 2018 in Review

Guggenheim Capital sold out of Protalix BioTherapeutics (PLX) in Q2 2018, closing a stake of 4,038 shares — an estimated $22K sold.

Guggenheim Capital first reported a position in PLX in Q3 2016 and held it in 7 quarters. The position peaked at $55K in Q1 2017. 36 funds tracked by Wall St. Rank hold PLX as of Q2 2018.

Guggenheim Capital reported no remaining Protalix BioTherapeutics position as of Q2 2018 after selling out during the quarter.
Guggenheim Capital sold 4,038 Protalix BioTherapeutics shares in Q2 2018, an estimated $22K.
Guggenheim Capital first reported a position in Protalix BioTherapeutics in Q3 2016 and held it in 7 quarters.
Guggenheim Capital's Protalix BioTherapeutics position peaked at $55K in Q1 2017.
36 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.